FBRX (STOCKS)
Forte Biosciences, Inc. Common Stock
$76.860000
+0.080000 (+0.10%)
Prev close: $76.780000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Paul A. Wagner
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,578.25M
- Employees
- 17
- P/E (TTM)
- -14.98
- P/B (TTM)
- 25.37
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $2.72M |
| Operating Expenses | $76.97M |
| Operating Income/Loss | -$76.97M |
| Income/Loss From Continuing Operations After Tax | -$75.86M |
| Income/Loss From Continuing Operations Before Tax | -$74.45M |
| Income Tax Expense/Benefit | $1.41M |
| Net Income/Loss | -$75.86M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$75.86M |
| Net Income/Loss Available To Common Stockholders, Basic | -$75.86M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.64 |
| Diluted Earnings Per Share | -$4.64 |
| Assets | $67.22M |
| Current Assets | $65.11M |
| Noncurrent Assets | $2.11M |
| Fixed Assets | $110.00K |
| Other Non-current Assets | $2.00M |
| Liabilities | $25.12M |
| Current Liabilities | $23.65M |
| Accounts Payable | $13.08M |
| Other Current Liabilities | $10.56M |
| Noncurrent Liabilities | $1.48M |
| Equity | $42.10M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $42.10M |
| Liabilities And Equity | $67.22M |
| Net Cash Flow From Operating Activities | -$59.34M |
| Net Cash Flow From Operating Activities, Continuing | -$59.34M |
| Net Cash Flow From Investing Activities | $18.68M |
| Net Cash Flow From Investing Activities, Continuing | $18.68M |
| Net Cash Flow From Financing Activities | $71.76M |
| Net Cash Flow From Financing Activities, Continuing | $71.76M |
| Net Cash Flow | $31.10M |
| Net Cash Flow, Continuing | $31.10M |
| Comprehensive Income/Loss | -$75.86M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$75.86M |
| Other Comprehensive Income/Loss | -$17.69M |